Research Frontiers And 3 Other Stocks Under $1 Insiders Are Buying

Research Frontiers和其他3只低於1美元的股票內部人士正在買入

Benzinga · 2023/12/13 21:29

The Dow Jones index closed higher by over 150 points on Tuesday. When insiders purchase or sell shares, it indicates their confidence or concern around the company's prospects. Investors and traders interested in penny stocks can consider this a factor in their overall investment or trading decision.

Below is a look at a few recent notable insider transactions for penny stocks. For more, check out Benzinga's insider transactions platform.

OLB Group

The Trade: The OLB Group, Inc. (NASDAQ:OLB) Chairman and CEO Ronny Yakov acquired a total of 22,315 shares an average price of $0.75. To acquire these shares, it cost around $16,739.
What's Happening: On Nov. 15, the company posted a wider-than-expected quarterly loss.
What OLB Group Does: The OLB Group Inc is a diversified fintech e-commerce merchant services provider and Bitcoin crypto mining enterprise.

Research Frontiers

The Trade: Research Frontiers Incorporated (NASDAQ:REFR) Director Darryl Daigle acquired a total of 7,750 shares at an average price of $0.97. To acquire these shares, it cost around $7,518.
What's Happening: On Nov. 2, Research Frontiers posted a narrower third-quarter loss.
What Research Frontiers Does: Research Frontiers Inc is engaged in the development and marketing of technology and devices to control the flow of light.

Check This Out: How To Earn $500 A Month From Oracle Stock After Q2 Earnings Results

Sadot Group

The Trade: Sadot Group Inc. (NASDAQ:SDOT) Director David Errington acquired a total of 10,000 shares at an average price of $0.40. The insider spent around $3,986 to buy those shares.
What's Happening: On Nov. 14, Sadot Group posted upbeat quarterly sales.
What Sadot Group Does: Sadot Group Inc operates in the food supply chain sector, connecting producers and consumers across the globe, delivering agri-commodities from producing geographies such as the Americas, Africa, and the Black Sea to consumer markets in Southeast Asia, China, and the Middle East/North Africa (MENA) region.

Forte Biosciences

The Trade: Forte Biosciences, Inc. (NASDAQ:FBRX) Director Paul A Wagner acquired a total of 29,776 shares at an average price of $0.65. The insider spent around $19,276 to buy those shares.
What's Happening: On Nov. 13, Forte Biosciences posted a wider third-quarter loss.
What Forte Biosciences Does: Forte Biosciences Inc is a biopharmaceutical company that is advancing through preclinical trials its product candidate, FB-102, which is a proprietary therapeutic molecule with potentially broad autoimmune applications in such indications as graft-versus-host disease ("GvHD"), vitiligo and alopecia areata ("AA").

Don't forget to check out our premarket coverage here

The Dow Jones index closed higher by over 150 points on Tuesday. When insiders purchase or sell shares, it indicates their confidence or concern around the company's prospects. Investors and traders interested in penny stocks can consider this a factor in their overall investment or trading decision.

道瓊斯指數週二收盤上漲超過150點。當內部人士購買或賣出股票時，這表明他們對公司前景的信心或擔憂。對細價股感興趣的投資者和交易者可以將其視爲其整體投資或交易決策中的一個因素。

Below is a look at a few recent notable insider transactions for penny stocks. For more, check out Benzinga's insider transactions platform.

以下是近期一些值得注意的細價股內幕交易。欲了解更多，請查看 本辛加的內幕交易 平台。

OLB Group

OLB 集團

The Trade: The OLB Group, Inc. (NASDAQ:OLB) Chairman and CEO Ronny Yakov acquired a total of 22,315 shares an average price of $0.75. To acquire these shares, it cost around $16,739.
What's Happening: On Nov. 15, the company posted a wider-than-expected quarterly loss.
What OLB Group Does: The OLB Group Inc is a diversified fintech e-commerce merchant services provider and Bitcoin crypto mining enterprise.

交易：OLB集團公司（納斯達克股票代碼：OLB）董事長兼首席執行官羅尼·雅科夫 共收購了22,315股股票 平均價格爲0.75美元。收購這些股票的成本約爲16,739美元。
發生了什麼：11月15日，該公司公佈的季度虧損超出預期。
OLB集團做什麼：OLB Group Inc是一家多元化的金融科技電子商務商業服務提供商和比特幣加密採礦企業。

Research Frontiers

研究前沿

The Trade: Research Frontiers Incorporated (NASDAQ:REFR) Director Darryl Daigle acquired a total of 7,750 shares at an average price of $0.97. To acquire these shares, it cost around $7,518.
What's Happening: On Nov. 2, Research Frontiers posted a narrower third-quarter loss.
What Research Frontiers Does: Research Frontiers Inc is engaged in the development and marketing of technology and devices to control the flow of light.

貿易：研究前沿公司（納斯達克股票代碼：REFR）董事達里爾·戴格爾 共收購了7,750股股票 平均價格爲0.97美元。收購這些股票的成本約爲7,518美元。
發生了什麼：11月2日，Research Frontiers公佈的第三季度虧損幅度較小。
Research Frontiers做什麼：Research Frontiers Inc從事控制光流的技術和設備的開發和營銷。

Check This Out: How To Earn $500 A Month From Oracle Stock After Q2 Earnings Results

看看這個： 第二季度業績公佈後如何每月從甲骨文股票中賺取500美元

Sadot Group

薩多特集團

The Trade: Sadot Group Inc. (NASDAQ:SDOT) Director David Errington acquired a total of 10,000 shares at an average price of $0.40. The insider spent around $3,986 to buy those shares.
What's Happening: On Nov. 14, Sadot Group posted upbeat quarterly sales.
What Sadot Group Does: Sadot Group Inc operates in the food supply chain sector, connecting producers and consumers across the globe, delivering agri-commodities from producing geographies such as the Americas, Africa, and the Black Sea to consumer markets in Southeast Asia, China, and the Middle East/North Africa (MENA) region.

交易：薩多特集團公司（納斯達克股票代碼：SDOT）董事戴維·埃靈頓 共收購了 10,000 股股票 平均價格爲0.40美元。知情人花了大約3,986美元購買了這些股票。
發生了什麼：11月14日，薩多特集團公佈了樂觀的季度銷售額。
薩多特集團做什麼：薩多特集團在食品供應鏈領域開展業務，連接全球生產商和消費者，將農產品從美洲、非洲和黑海等生產地區運送到東南亞、中國和中東/北非（MENA）地區的消費市場。

Forte Biosciences

Forte 生物科學

The Trade: Forte Biosciences, Inc. (NASDAQ:FBRX) Director Paul A Wagner acquired a total of 29,776 shares at an average price of $0.65. The insider spent around $19,276 to buy those shares.
What's Happening: On Nov. 13, Forte Biosciences posted a wider third-quarter loss.
What Forte Biosciences Does: Forte Biosciences Inc is a biopharmaceutical company that is advancing through preclinical trials its product candidate, FB-102, which is a proprietary therapeutic molecule with potentially broad autoimmune applications in such indications as graft-versus-host disease ("GvHD"), vitiligo and alopecia areata ("AA").

交易：Forte Biosciences, Inc.（納斯達克股票代碼：FBRX）董事保羅·瓦格納 共收購了29,776股股票 平均價格爲0.65美元。內幕人士花費了大約19,276美元購買了這些股票。
發生了什麼：11月13日，Forte Biosciences公佈了更大的第三季度虧損。
Forte Biosciences的所作所爲：Forte Biosciences Inc是一家生物製藥公司，正在通過臨床前試驗推進其候選產品 FB-102，這是一種專有的治療分子，在移植物抗宿主病（“gvHD”）、白癜風和脫髮（“AA”）等適應症中具有廣泛的自身免疫應用。

Don't forget to check out our premarket coverage here

別忘了在這裏查看我們的上市前報道

譯文內容由第三人軟體翻譯。

以上內容僅用作資訊或教育之目的，不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。